Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118


Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland.

Barkoff AM, Mertsola J, Guillot S, Guiso N, Berbers G, He Q.

Clin Vaccine Immunol. 2012 Oct;19(10):1703-4. Epub 2012 Aug 22. No abstract available.


Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.

Bottero D, Gaillard ME, Fingermann M, Weltman G, Fernández J, Sisti F, Graieb A, Roberts R, Rico O, Ríos G, Regueira M, Binsztein N, Hozbor D.

Clin Vaccine Immunol. 2007 Nov;14(11):1490-8. Epub 2007 Aug 15.


Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.

Martin SW, Pawloski L, Williams M, Weening K, DeBolt C, Qin X, Reynolds L, Kenyon C, Giambrone G, Kudish K, Miller L, Selvage D, Lee A, Skoff TH, Kamiya H, Cassiday PK, Tondella ML, Clark TA.

Clin Infect Dis. 2015 Jan 15;60(2):223-7. doi: 10.1093/cid/ciu788. Epub 2014 Oct 9.


Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.

Williams MM, Sen K, Weigand MR, Skoff TH, Cunningham VA, Halse TA, Tondella ML; CDC Pertussis Working Group..

Emerg Infect Dis. 2016 Feb;22(2):319-22. doi: 10.3201/eid2202.151332.


Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia.

Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, Wood N, McIntyre P, Marshall H, Guiso N, Keil AD, Lawrence A, Robson J, Hogg G, Lan R.

Emerg Infect Dis. 2014 Apr;20(4):626-33. doi: 10.3201/eid2004.131478.


[Modern strains of Bordetella pertussis: immunobiological properties and vaccine improvement].

Shinkarev AS, Mertsalova NU, Mazurova IK, Borisova OIu, Zakharova NS, Ozeretskovskaia MN, Zaĭtsev EM, Poddubikov AV, Britsina MV, Bazhanova IG.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):20-5. Russian.


Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.

Podda A, Carapella De Luca E, Titone L, Casadei AM, Cascio A, Bartalini M, Volpini G, Peppoloni S, Marsili I, Nencioni L, et al.

J Pediatr. 1993 Jul;123(1):81-4.


[Immunobiologic activity of Bordetella pertussis strains defective in various virulence factors].

Smirnov VD, Chuprinina RP, Siundiukova RA, Maksiutov RV.

Zh Mikrobiol Epidemiol Immunobiol. 1989 Mar;(3):8-10. Russian.


Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.

Komatsu E, Yamaguchi F, Abe A, Weiss AA, Watanabe M.

Clin Vaccine Immunol. 2010 May;17(5):807-12. doi: 10.1128/CVI.00449-09. Epub 2010 Mar 31.


Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.

Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, Williams MM, Bowden KE, Burgos-Rivera B, Qin X, Messonnier N, Tondella ML.

Clin Vaccine Immunol. 2014 Feb;21(2):119-25. doi: 10.1128/CVI.00717-13. Epub 2013 Nov 20.


Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.

Storsaeter J, Hallander HO, Gustafsson L, Olin P.

Vaccine. 1998 Dec;16(20):1907-16.


Pertactin-negative variants of Bordetella pertussis in the United States.

Queenan AM, Cassiday PK, Evangelista A.

N Engl J Med. 2013 Feb 7;368(6):583-4. doi: 10.1056/NEJMc1209369. No abstract available.


Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis.

Isacson J, Trollfors B, Hedvall G, Taranger J, Zackrisson G.

Scand J Infect Dis. 1995;27(3):273-7.


Role of pertactin in pertussis vaccines: the jury is still out.

Desauziers E, Danve B, Decker MD, Veitch K.

J Infect Dis. 2004 Apr 1;189(7):1332-3; author reply 1333-5. No abstract available.


Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.

Grimprel E, Bégué P, Anjak I, Njamkepo E, François P, Guiso N.

Clin Diagn Lab Immunol. 1996 Jan;3(1):93-7.


Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen.

Hijnen M, Mooi FR, van Gageldonk PG, Hoogerhout P, King AJ, Berbers GA.

Infect Immun. 2004 Jul;72(7):3716-23.

Supplemental Content

Support Center